A Study of the ILB-3101 in Patients with Advanced Solid Tumors

Summary

ILB-3101 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of ILB-3101 in Chinese advanced solid tumor patients.

Timeline

Start

2024-10-30

Primary completion

2025-12

Completion

2026-03

Drugs

Indications